All RA patients ( n = 72) | Anti-CII-negative RA patients ( n = 48) | Anti-CII-positive (>29 AU/ml) RA patients ( n = 24) | P (between anti-CII-negative and all anti-CII-positive patients) | Anti-CII highly positive (>470 AU/ml) RA patients ( n = 9) | P (between anti-CII-negative and highly anti-CII-positive patients) | |
---|---|---|---|---|---|---|
Mean age at onset (years) | 59.6 (14.4) | 59.7 (15.0) | 59.4 (30.5) | NS | 63.3 (13.7) | NS |
% females | 76 (55/72) | 79.2 (38/48) | 70.8 (17/24) | NS | 66.7 (6/9) | NS |
Mean disease duration at inclusion (months) | 5.5 (2.6) | 6.1 (2.8) | 4.2 (1.6) | 0.005 | 4.4 (1.4) | NS (0.08) |
RF-positive (%; number positive/total number) | 51 (36/71) | 50 (24/48) | 52 (12/23) | NS | 44 (4/9) | NS |
Anti-CCP2-positive, (%; number positive/total number) | 47 34/72 | 48 (23/48) | 37.5 (9/24) | NS | 33.3 (3/9) | NS |
CRP (mg/l) | 31 (40) | 20 (18) | 53 (60) | 0.020 | 46 (34) | 0.007 |
ESR (mm/hour) | 28 (22) | 24 (18) | 36 (27) | NS | 41 (27) | 0.039 |
Physician’s assessment of disease activity (0 to 4) | 2.1 (0.8) | 2.0 (0.8) | 2.3 (0.6) | NS | 2.4 (0.5) | NS |
Number of swollen joints | 10 (5) | 8 (5) | 12 (6) | 0.022 | 10 (5) | NS |
Number of tender joints | 9 (5) | 9 (5) | 8 (6) | NS | 8 (3) | NS |
DAS28 | 5.1 (1.1) | 5.0 (1.0) | 5.2 (1.3) | NS | 5.5 (0.9) | NS |
Global VAS | 43 (27) | 45 (27) | 39 (28) | NS | 46 (29) | NS |
Pain VAS | 45 (23) | 49 (23) | 38 (21) | NS | 37 (21) | NS |
HAQ | 0.99 (0.59) | 0.97 (0.58) | 1.02 (0.61) | NS | 1.33 (0.55) | NS |
Baseline Larsen score | 9.71 (10.42) | 9.36 (10.69) | 10.37 (10.05) | NS | 12.28 (6.52) | NS (0.12) |
% of patients starting DMARD therapy at baseline | 92 (66/72) | 96 (46/48) | 83 (20/24) | NS | 89 (8/9) | NS |